DELIVER (veterinary product)

Dyne Therapeutics Reports Positive Results for Duchenne Drug DYNE-251, Plans FDA Approval Submission

2 days ago talkbio0Tagged Accelerated, Approved, Biological Factors, Breakthrough Therapy Designation, Clinical Trials, DELIVER (veterinary product), Dyne Therapeutics, DYNE-251, License Application, Muscular Dystrophy, Duchenne, United States Food and Drug Administration

Dyne Therapeutics; DYNE-251; Duchenne muscular dystrophy; exon 51 skipping; DELIVER trial; FDA Breakthrough Therapy Designation; Biologics License Application; accelerated approval

Dyne Therapeutics’ z-rostudirsen Shows Durable Efficacy, Supporting Positive Regulatory Outlook

1 month ago talkbio0Tagged Accelerated, Approved, Biological Markers, Clinical Trials, DELIVER (veterinary product), Dyne Therapeutics, Effectiveness, Functional improvement, Muscular Dystrophy, Duchenne, regulatory approval, z-rostudirsen

Dyne Therapeutics; z-rostudirsen; DELIVER trial; Duchenne muscular dystrophy (DMD); durable efficacy; regulatory approval; biomarkers; functional improvement; accelerated approval

Dyne Therapeutics Faces Setbacks Despite Promising DMD Study Results

1 year ago talkbio0Tagged Adverse event, DELIVER (veterinary product), DMD, Duchenne, Dyne veterinary drug, DYNE-251, Executive Departures, Muscular Dystrophy, Muscular Dystrophy, Duchenne

Dyne Therapeutics, Duchenne Muscular Dystrophy (DMD), DELIVER trial, DYNE-251, adverse events, executive departures